Dr. Lal Path Labs enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


32,040	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
665	665	619	475	414
33.1	33.1	33.8	36.1	33.2
0.0	0.0	0.0	83.3	237
31,408	—	—	—	—
−665	−665	−619	−391	−177
₹1,873.97	—	—	—	—

2,541	2,541	2,207	1,969	1,936
0.0%	0.0%	0.0%	4.2%	12.2%

10.86×	—	—	—	—
37.49×	—	—	—	—
47.15×	—	—	—	—
67.94×	—	—	—	—
2,891	2,763	2,461	2,227	2,017
838	783	696	609	490
666	621	554	466	340
—	636	569	535	456
462	462	515	478	411
—	457	510	470	400
—	173	53.9	57.5	44.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health

₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,040 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	32,040.1
- Cash, Equiv & ST Investments	413.6	474.7	619.3	665.4	665.4
+ Minority Interest	33.2	36.1	33.8	33.1	33.1
+ Total Debt	236.6	83.3	0.0	0.0	0.0
Enterprise Value	—	—	—	—	31,407.8
Net Debt (memo)	-177.0	-391.4	-619.3	-665.4	-665.4
EV per Share	—	—	—	—	1,873.97

Total Capital	1,936.1	1,968.7	2,206.5	2,541.3	2,541.3
Total Debt/Total Capital	12.22	4.23	0.00	0.00	0.00

EV/Sales	—	—	—	—	10.86
EV/EBITDA	—	—	—	—	37.49
EV/EBIT	—	—	—	—	47.15
EV/Free Cash Flow	—	—	—	—	67.94
Reference Items — Trailing FY Values
Sales	2,016.9	2,226.6	2,461.4	2,762.9	2,890.8
EBITDA	489.9	609.3	695.5	782.5	837.7
EBIT	339.7	465.7	553.6	620.7	666.1
Operating Cash Flow	456.0	535.4	568.8	635.7	—
Free Cash Flow	411.4	477.9	514.9	462.3	462.3
FCFF (free cash flow to the firm)	400.1	469.6	510.2	456.9	—
Capital Expenditure	44.6	57.5	53.9	173.4	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.